RecruitingNCT05977023
NMDA enhancer or placebo for cognitive challenges and stress during bipolarity
About this title
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
Read the official source — NCT05977023Medication studyAges 18–65Taiwan
Understand this study
Who could participate?
This study is for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
You continue your current treatment and are randomly assigned to an NMDA-enhancing study product or placebo (an inactive comparison treatment) for eight weeks. Thinking skills and quality of life are assessed at the start and at eight weeks, with symptom and side-effect assessments at weeks 0, 2, 4, 6 and 8.
- Listed locations
- TaichungSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 4, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 90
- Sponsor
- China Medical University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Taiwan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05977023
- Official title
Show the full official title
NMDA Receptor Modulation for the Treatment of Cognitive Impairment and Perceived Stress in Bipolar I Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Taichung
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is China Medical University Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including NMDAE and Placebo Cap.
Who can participate?
This study is for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
